ANTX (AN2 Therapeutics) Net Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. AN2 Therapeutics's Net Income for the three months ended in Sep. 2024 was $-12.75 Mil. AN2 Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, AN2 Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for AN2 Therapeutics's Net Margin % or its related term are showing as below:

ANTX's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

AN2 Therapeutics Net Margin % Historical Data

The historical data trend for AN2 Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AN2 Therapeutics Net Margin % Chart

AN2 Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

AN2 Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of AN2 Therapeutics's Net Margin %

For the Biotechnology subindustry, AN2 Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AN2 Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's Net Margin % falls into.

AN2 Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

AN2 Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-64.732	/	0
	=	%

AN2 Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin	=	Net Income (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-12.747	/	0
	=	%

AN2 Therapeutics (NAS:ANTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

AN2 Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027

Website

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Executives

Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Robin Shane Readnour	director	3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Eric Easom	director, officer: Chief Executive Officer	171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kabeer Aziz	director	376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Adjuvant Global Health Technology Fund De, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Kevin Michael Krause	officer: Chief Strategy Officer	369 27TH STREET, SAN FRANCISCO CA 94131
Joshua M Eizen	officer: See Remarks	3023 MONTBRETIA WAY, SAN RAMON CA 94582
Margaret M Fitzpatrick	director	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Ra Capital Nexus Fund Ii, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Melvin K Spigelman	director	THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Sanjay Chanda	officer: Chief Development Officer	C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Adjuvant Global Health Technology Fund, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak	officer: Chief Accounting Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Lucy Day	officer: Chief Financial Officer	2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301